Resistance To BCR-ABL Targeting Drugs
In the case of Gleevec (Imatinib), which targets the BCR-ABL fusion gene in chronic myeloid leukemia, resistance often develops through a mutation that changes the shape of the binding site of the drug. Sequential application of drugs can lead to the sequential evolution of resistance mutations to each drug in turn.
Gleevec is not as selective as was originally thought. It turns out that it targets other tyrosine kinase genes and can be used to control gastrointestinal stromal tumors (GISTs) that are driven by mutations in c-KIT. However, patients with GIST sometimes relapse with additional mutations in c-KIT that make the cancer cells resistant to Gleevec.
Read more about this topic: Somatic Evolution In Cancer, Somatic Evolution in Therapeutic Resistance
Famous quotes containing the words resistance to, resistance and/or drugs:
“You may either win your peace or buy it: win it, by resistance to evil; buy it, by compromise with evil.”
—John Ruskin (1819–1900)
“It is not the first duty of the novelist to provide blueprints for insurrection, or uplifting tales of successful resistance for the benefit of the opposition. The naming of what is there is what is important.”
—Ian McEwan (b. 1938)
“There is not much sense in suffering, since drugs can be given for pain, itching, and other discomforts. The belief has long died that suffering here on earth will be rewarded in heaven. Suffering has lost its meaning.”
—Elisabeth Kübler-Ross (b. 1926)